Mira Pharmaceuticalsの空売り状況は、投資家がMira Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Mira Pharmaceuticals (NASDAQ:MIRA) 株価情報, 空売り情報

Mira Pharmaceuticals

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals Inc

MIRAI Corp

MIRAIT One Corp

MIRAMAR RESOURCES LTD by MIRAMAR RESOURCES LTD

MIRATI THERAPEUTICS INC COM

MIRACLE ENTMT INC by Miracle Entertainment Inc.

Miracle Entertainment Inc

MIRAGE ENERGY CORP by Mirage Energy Corporation

Mirage Energy Corp

MIRAMAR HOTE & INVST CO by Miramar Hotel & Investment Co., Ltd.

Miramar Hotel & Investment Co Ltd

TAKARA LEBEN CO LTD by Takara Leben Co., Ltd.

Mirarth Holdings Inc

MIRASOL RESOURCES LTD by Mirasol Resources Ltd.

Mirasol Resources Ltd

Miratap Inc

MIRAVANT MEDICAL TECHS by Miravant Medical Technologies

Miravant Medical Technologies

Telsey Advisory Group analyst Dana Telsey maintains Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) with a Outperform and maintains $340 price target.

News

Price Target

Analyst Ratings

BURL

Telsey Advisory Group Maintains Outperform on Burlington Stores, Maintains $340 Price Target

Webus International Limited ("Webus," the "Company," "we," "our," or "us") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETO#NASDAQ">WETO</a>), a recognized provider of AI-driven mobility solutions specializing in premium, customizable chauffeur services for travelers worldwide, today announced two complementary strategic developments that significantly advance its vision of a seamless, borderless travel ecosystem.&nbsp;
The Company is exploring a financing strategy of up to US$300 million (the "Financing") through a diversified mix of non-equity funding vehicles to establish an XRP reserve for supporting global payment solutions. This approach includes the potential use of available cash reserves, bank lending, shareholder guarantees, and third-party institutional-backed credit facilities from traditional banks. By leveraging these non-dilutive financing methods, the Company seeks to maintain capital flexibility, support long-term growth, and preserve shareholder value while advancing its strategic objective in the digital asset and cross-border paryment space. In addition, the Company renewed its nationwide mobility partnership (the "Partnership") with Tongcheng Travel Holdings Ltd. (HKSE: 0780.HK), one of China's largest online travel platforms.

Financing

WETO

Webus International Announces Strategic $300M Non-Equity Financing Plan To Establish XRP Reserve For Global Payment Solutions; Renews Nationwide Mobility Partnership With Tongcheng Travel

Offerings

BULL

BULLZ

Webull Issues Notice Of Redemption For All Outstanding Incentive Warrants Of 'BULLZ' To Be Redeemed On June 30, 2025 At $0.01 Per Warrant Unless Exercised At $10.00 Per Share Before Deadline

Agilent Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45656371/agilent-reports-second-quarter-fiscal-year-2025-financial-results" rel="noreferrer noopener">second-quarter 2025</a> sales of $1.67 billion on Wednesday, almost in line with the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.63 billion</a>, representing growth of 6% reported and up 5.3% core year-over-year.
The Life Sciences and Diagnostics Markets Group (LDG) reported second-quarter revenue of $654 million, an increase of 8% reported and 3% core&nbsp;year-over-year. LDG&#8217;s operating margin for the quarter was 19.7%.
The Agilent CrossLab Group (ACG) reported second-quarter revenue of $713 million, an increase of 7% reported and 9% core year-over-year. ACG&#8217;s operating margin for the quarter was 32.4%.
The Applied Markets Group (AMG) reported second-quarter revenue of $301 million, a decrease of 1% reported and flat core year-over-year. AMG&#8217;s operating margin for the quarter was 19.5%.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45655674/rocket-pharmas-gene-therapy-future-clouded-by-regulatory-uncertainty" rel="noreferrer noopener">Rocket Pharma&#8217;s Gene Therapy Future Clouded By Regulatory Uncertainty</a>
The <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">analytical and clinical laboratory</a> technologies provider reported adjusted earnings of $1.31 per share, up from $1.22 a year ago, beating the consensus of $1.26.
&#8220;The Agilent team delivered strong second-quarter results in a highly dynamic market environment,&#8221; said Agilent President and CEO Padraig McDonnell. &#8220;That is in large part due to our Ignite Transformation, which is driving our financial success as it&#8217;s become our core enterprise delivery engine and operating model. Ignite represents a decisive shift to fuel accelerated profitable growth and operational excellence at Agilent.&#8221;
The company&#8217;s&nbsp;operating margin <a target="_blank" href="https://in.investing.com/news/transcripts/earnings-call-transcript-agilent-technologies-q2-2025-beats-forecasts-stock-rises-93CH-4852010" rel="noreferrer noopener">was</a> 25.1% as it absorbed some incremental tariff costs.
In the earnings conference call, McDonnell said, &#8220;Through our tariff task force enabled by our Ignite operating model, we feel that we are able to mitigate most of the impact in 2025 and fully mitigate in 2026 even when considering recent developments on the U.S.-EU tariffs.&#8221;
Agilent reaffirmed fiscal 2025 adjusted earnings of $5.54-$5.61 per share compared to the consensus of $5.55.
The company raised sales guidance from $6.68 billion-$6.76 billion to $6.73 billion-$6.81 billion compared to the consensus of $6.73 billion.
The full-year revenue outlook represents growth of 3.4%-4.6% reported while maintaining core growth of 2.5%-3.5%
Based on the current tariff rates, Agilent estimates that the gross incremental tariff exposure in the second half will be $50 million. This is on top of the roughly $10 million already absorbed in the first half.
The company anticipates potential additional tariff impacts if U.S.-EU tariffs increase, which could add $40 million in gross exposure in the second half of 2025.
The outlook for third-quarter revenue is expected to be $1.65 billion-$1.68 billion versus a consensus of $1.65 billion, representing a growth of 4.2% to 6.1% reported and up 1.7% to 3.6% core.
Agilent sees Q3 adjusted earnings of $1.35-$1.37 versus a consensus of $1.39.
Price Action: A stock is trading higher by 5.52% to $117 premarket at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45634160/elon-musks-neuralink-hits-9-billion-valuation-with-new-funding" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Neuralink Hits $9 Billion Valuation With New Funding</a></li>
</ul>
Image via Shutterstock

Earnings

Guidance

Health Care

Movers

General

Agilent Braces For Potential US-EU Tariff Hike, Maintains Annual Outlook

PepGen Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) announced on Wednesday that it will focus on advancing its myotonic dystrophy type 1 (DM1) program, currently in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45656401/pepgen-to-focus-on-development-of-promising-dm1-program-following-10-mgkg-pgn-edo51-update" rel="noreferrer noopener">Phase 2 clinical development</a>.
The company voluntarily discontinued the development of PGN-EDO51 and intends to wind down all Duchenne muscular dystrophy (DMD)-)-related research and development activities.
The decision is based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study of PGN-EDO51 in DMD patients amenable <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">to exon 51 skipping</a>.
In the CONNECT1 study&#8217;s 10 mg/kg cohort (n=4), PGN-EDO51 increased exon 51 skipped transcripts to 4.26% (a mean increase of 3.5%); however, total dystrophin only increased to 0.59% of normal levels (a mean increase of 0.36%).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44120665/pepgen-to-voluntarily-pause-mid-stage-duchenne-muscular-dystrophy-study-stock-falls" rel="noreferrer noopener">PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls</a>
The safety profile of PGN-EDO51 continued to be generally favorable and all treatment-related adverse events were mild. No serious adverse events were reported in the study.
&#8220;We are disappointed by the dystrophin results observed in the 10 mg/kg dose cohort in CONNECT1, as it was our hope that we could improve upon existing therapies for patients in a more profound way,&#8221; said James McArthur, president and CEO of PepGen.
Paul Streck, executive vice president and head of R&amp;D at PepGen, continued, &#8220;PGN-EDODM1, PepGen&#8217;s investigational drug in development for DM1, has already demonstrated robust target engagement after a single 10 mg/kg dose in patients that resulted in mean mis-splicing correction of 29% with a favorable emerging safety profile as of February 24, 2025, the most recent safety update.&#8221;
PepGen expects to report data from its FREEDOM-DM1 15 mg/kg cohort in patients with DM1 during the second half of 2025. FREEDOM is a Phase 1 single ascending dose, randomized, placebo-controlled clinical trial, with endpoints including safety, 28-day splicing correction, and functional benefit measures.
The company also expects to report data from the 5 mg/kg cohort of its FREEDOM2-DM1 study in DM1 patients in the first quarter of 2026. FREEDOM2 is a Phase 2 multiple ascending dose, randomized, placebo-controlled clinical trial with endpoints following four doses, including safety, splicing correction, and functional benefit measures.
Price Action: At the last check on Thursday, PEPG stock was down 6.69% at $1.47 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45658018/box-growth-from-large-deals-partner-expansion-and-new-pricing-lifts-wall-street-outlook" target="_blank" rel="noreferrer noopener">Box Growth From Large Deals, Partner Expansion, And New Pricing Lifts Wall Street Outlook</a></li>
</ul>
Photo: Shutterstock

Biotech

Trading Ideas

PEPG

PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate

Galxe recently announced the launch of a new community engagement platform, <a href="https://www.benzinga.com/topic/web3">dubbed "Starboard."</a>
But the new platform is no hard turn for the company, which claims to have onboarded 34 million users into Web3 through its Quest platform. With the new platform, they intend to transition their customer onboarding presence into community management. "Starboard represents an additional level to this core capability, giving projects more insight into their communities that they can use to drive powerful growth," Galxe&#8217;s Head of GTM Patrick Young says.
See Also: <a href="https://www.benzinga.com/25/05/45668187/nvidia-faces-bipartisan-backlash-over-its-shanghai-facility-amid-significant-national-and-economic-security-threat-report">Nvidia Faces Bipartisan Heat Over Its Shanghai Facility Amid &#8216;Significant&#8217; National And Economic Security Threat</a>
Galxe has positioned Starboard as distinct from competitors like Layer3, Zealy, and RabbitHole. It tracks the life cycle of the client using an "Aura" score for off-chain metrics, like the impact of a social media post, alongside on-chain metrics like trading volume, TVL growth, and more.
"Galxe has always played a broader role in web3 growth, offering not only tools for initial engagement but also infrastructure for identity verification, distribution of rewards for long-term community members, and more," Young said. "With Starboard, teams can now double down on their highest-value contributors, allowing them to build highly engaged, long-term communities."
Galxe teamed with 20 Web3 companies in this launch. Plume Network, 0G Labs, Dango, RollDex, KRNL, Vanilla Finance, GRVT, Irys, Quranium, Lightlink, Zeta Chain, Cooking City, ChainOpera AI, Aspecta, Zerobase, Bitfi, Analog, Dabba Network and SPACE ID are among its partners.
Plume Network has contributed $450,000 to the collective rewards pool. Dango has committed 1 percent of its total token supply, and OG Labs has committed over $100,000. 
"Similar to Galxe Quest, which has found success through a model where projects fund reward pools to incentivize user participation. Starboard operates on the same principle. Projects provide reward pools to attract core contributors to support and grow their ecosystems, which is a fundamental, ongoing need," Young said.
Young pointed out that as more projects join the platform, the dataset will expand, and the accumulated data will become increasingly valuable to the Web3 market.
It's questionable whether a community can truly be the utility of a project. As many memecoin projects suggested in 2024, the community is one of the most powerful assets of any Web3 project. Observers consider tools like this part of the maturation of the blockchain space. As we grow, we need to know ourselves and our customers better, on-chain and off. It remains to be seen whether Galxe will successfully establish the new platform as a standard for blockchain projects. Whether their data moat will become a true differentiator in a crowded market of Web3 growth tools is also uncertain. Still, solutions like this will be in demand as blockchain technology becomes more mainstream.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45667896/hedera-co-founder-predicts-that-everything-of-value-will-be-tokenized">Hedera Co-Founder Predicts That &#8216;Everything Of Value&#8217; Will Be Tokenized</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Fintech news covering the emerging Financial Technology services sector

Fintech

Exclusives

Tech

Interview

Galxe Launches New Web3 Community Building Platform

Euroseas Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESEA#NASDAQ">ESEA</a>, the "Company" or "Euroseas"))), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes, announced today that it has signed an agreement to sell M/V Marcos V, an 6,350 teu intermediate containership built in 2005, to an unaffiliated third party, for $50 million. The vessel is scheduled to be delivered to its buyer in October 2025. The Company is expected to recognize a gain on the sale in excess of $8.50 million, or $1.20 per share.

Asset Sales

ESEA

Euroseas Signs Agreement To Sell 6,350 Containership M/V Marcos V For $50M, With Expected Gain Of Over $8.5M Or $1.20 Per Share Upon October 2025 Delivery

A Reddit user claims he took $100,000 from a recent <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/04/44658576/more-homes-hit-the-market-but-pending-sales-dip-as-buyers-hesitate">house sale</a> and put it all into UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) stock without telling his wife, who believes the money is safely tucked away in a <a href="https://www.benzinga.com/money/best-high-yield-savings-accounts">high-yield savings account</a>.
<h2 class="wp-block-heading">A High-Stakes Secret</h2>
In the popular <a href="https://www.reddit.com/r/wallstreetbets/comments/1kt8b8d/i_took_100k_from_our_house_sale_and_bought_303/">r/wallstreetbets</a> subreddit, the investor wrote, &#8220;Wife said, ‘Put it somewhere safe.' I said, hold my beer b&#x2A;tch, then funneled $100K into <a href="https://www.benzinga.com/money/fidelity-investments-review">Fidelity</a> and bought 303 shares of UnitedHealth.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
He justified the risky move by saying, &#8220;Because America's not gonna stop getting sick. Fat, old, diabetic, stressed out, healthcare is the last thing people cut. And UNH is built like a tank. Major insider buying too.&#8221;
UnitedHealth stock was down over 41% year to date when the UNH investor posted about his investment late May 22.&nbsp;
The r/wallstreetbets comment section exploded with reactions, ranging from jokes about impending divorce to harsh warnings. The top comment read, &#8220;Make sure you put something aside to pay for your divorce lawyer,&#8221; to which OP replied, &#8220;I still have the $20K… it's either for the lawyer or <a href="https://www.benzinga.com/money/options-trading-strategies">call options</a>.&#8221;
Another comment read, &#8220;You don't need a lawyer if there's nothing left to fight over,&#8221; while another person remarked, &#8220;This is the f&#x2A;&#x2A;ing sh&#x2A;t I signed up for,&#8221; reflecting the subreddit's mix of chaos, comedy, and high-risk investing.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
Others chimed in with classic WallStreetBets flair: &#8220;<a href="https://www.benzinga.com/25/05/45308441/risk-appetite-hits-record-high-0dte-options-hit-67-of-total-volumes2-million-average-contracts-in-q1">0dte puts</a> on this guy's marriage at open,&#8221; and &#8220;Big Balls, Big Calls.&#8221;&nbsp;
Critics, though, pointed to the serious implications. &#8220;If a financial decision needs to be hidden from your <a href="https://www.benzinga.com/personal-finance/24/03/37879066/kevin-oleary-warns-couples-maintain-your-own-financial-identity-but-indiana-university-study-say">significant other</a>, that&#8217;s usually a good indication that it&#8217;s dumb,&#8221; one comment noted. Another added, &#8220;That's financial infidelity. Your marriage is done.&#8221;
<h2 class="wp-block-heading">Inside the UNH Crisis</h2>
Meanwhile, UnitedHealth has <a href="https://www.benzinga.com/25/05/45558758/as-unitedhealth-group-lost-an-unthinkable-140-billion-in-market-cap-since-april-analysts-weigh-in-on-the-path-ahead">had a rough stretch</a>. The company missed earnings expectations last quarter and is under pressure from several fronts. It abruptly <a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance">replaced its CEO</a>, Andrew Witty, with former CEO Stephen Hemsley. Hemsley then <a href="https://www.benzinga.com/general/health-care/25/05/45486314/unitedhealth-ceo-other-insiders-buy-millions-in-stock-as-it-sinks-over-23-in-a-week-move-gets-mixed-reaction">bought in $25 million worth of shares</a>, joining other insiders who collectively purchased millions more in stock.
According to <a href="https://www.secform4.com/insider-trading/731766.htm">filings</a> with the Securities and Exchange Commission, board members Timothy Flynn, Kristen Gil and John Noseworthy purchased shares worth $49,786, $1,003,329 and $93,647, respectively. CFO John Rex added another $5 million.
It also remains under a shadow after the December <a href="https://www.benzinga.com/24/12/42322999/unitedhealth-deeply-saddened-and-shocked-by-death-of-brian-thompson-new-york-police-share-update-on-case-with-10k-reward-offered-rockefeller-center-tree-lighting-to-go-on">assassination</a> of its insurance unit CEO, Brian Thompson.&nbsp;
See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
<h2 class="wp-block-heading">Mixed Sentiment From Investors</h2>
Despite all this, some investors see a long-term opportunity. One commenter argued, &#8220;UNH is too big to fail. The stock will go back up over the next couple years.&#8221;
Others are more skeptical. Investment YouTuber Jeremy Lefebvre called the stock &#8220;straight trash&#8221; <a href="https://x.com/HolySmokas/status/1923806928951775450">on X</a>, comparing it to Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) and warning that UnitedHealth is entering a long stretch of regulatory trouble and bad press.
However, the original poster seems to agree with the bulls, doubling down with: &#8220;I'm not finished. Let's see how the stock moves. I will keep you posted.&#8221;
As of now, his wife is still in the dark.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

'America's Not Gonna Stop Getting Sick,' Says Investor Who Put $100K Into UNH Stock. His Wife Still Thinks It's Sitting In A Savings Account

WIIM

LTRN

LTRN stock has given up its prior gain. Lantern Pharma shares were trading higher after the company announced preclinical data for LP-184.

Inspira&#x2122; Technologies OXY B.H.N. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IINN#NASDAQ">IINN</a>) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic shift to accelerate the commercialization of its U.S. FDA (Food and Drug Administration)-cleared INSPIRA&#x2122; ART100 system (the "ART100"), while maintaining the development and regulatory pathways of its portfolio of products. The Company is currently engaged in active sales discussions in multiple locations.
This development follows the initial clinical implementation of the ART100 system in medical centers in the U.S., where the device has been used to treat patients in real-world clinical settings.

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies Announces Strategic Shift To Accelerate Commercialization Of FDA-Cleared INSPIRA ART100 System, While Maintaining Development, Regulatory Pathways Of Its Portfolio

Synopsys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) shares are trading higher premarket on Thursday after the company reported second-quarter 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45656422/synopsys-posts-financial-results-for-second-quarter-fiscal-year-2025" rel="noreferrer noopener">after market close on Wednesday</a>.
The company reported revenue of $1.60 billion, in line with the consensus estimate. The adjusted EPS of $3.67 <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">beat the street view of $3.38</a>.
Gross profit increased to&nbsp;$1.29 billion&nbsp;from&nbsp;$1.15 billion in the year-ago quarter, and the operating income rose to&nbsp;$376.4 million&nbsp;from&nbsp;$332.1 million&nbsp;in the prior year quarter.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45663228" rel="noreferrer noopener">US Escalates Tech War With China, New Export Curbs To Hit Cadence, Synopsys As EDA Software, Chemicals And Tools Face License Requirements: Report</a>
Sassine Ghazi, president and CEO of Synopsys, said, &#8220;The mega trends of AI, software-defined systems, and silicon proliferation continue to drive our growth. These trends are increasing design complexity and costs, while also increasing compute performance and energy demands. Synopsys is a trusted partner in addressing these challenges and a leader in applying AI to help customers innovate faster.&#8221;
&#8220;In a dynamic macro environment, Synopsys continues to execute with strong Q2 results on the top and bottom line,&#8221; said&nbsp;Shelagh Glaser, CFO of Synopsys. &#8220;We&#8217;re poised to deliver a solid second half, and we&#8217;re reaffirming our full-year revenue and operating margin guidance, reflecting our confidence in the business and continued healthy demand for our products.&#8221;
Synopsys increased its adjusted EPS guidance for FY25 to $15.11-$15.19, from the previous outlook of $14.88-$14.96. This new range surpasses the <a target="_blank" href="https://www.benzinga.com//node/44000473" rel="noreferrer noopener">analyst consensus estimate of $14.89</a>.
The company has, however, reaffirmed its FY2025 sales outlook at $6.75 billion-$6.80 billion, which aligns with the $6.77 billion analyst estimate.
Synopsys expects&nbsp;third-quarter revenue of&nbsp;$1.75 billion–$1.78 billion versus estimates of&nbsp;$1.76 billion&nbsp;and adjusted EPS of&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$3.82-$3.87&nbsp;vs. consensus of&nbsp;$3.39</a>.
These new targets reflect Synopsys&#8217; shift in its fiscal year definition. Previously, the fiscal year concluded on the Saturday closest to October 31st, but it will now end precisely on October 31st each year.
This change results in a shorter first half of fiscal year 2025 by ten days, compensated by an extra two days in the second half, leading to a total of eight fewer days in fiscal year 2025 compared to fiscal year 2024.
The <a target="_blank" href="https://www.benzinga.com/markets/equities/25/05/45663228/us-escalates-tech-war-with-china-new-export-curbs-hit-cadence-synopsys-as-eda-software-chemicals-and-tools-face-license-requirements-report" rel="noreferrer noopener">latest U.S. restrictions</a>, designed to limit China&#8217;s access to essential technology, are anticipated to have a notable impact on major electronic design automation (EDA) software providers Cadence Design Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) and Synopsys, which have significant exposure.
According to Reuters, the U.S. Commerce Department has informed companies about expanded controls affecting EDA software, butane and ethane chemicals, machine tools, and aviation equipment.
Addressing these reports, Synopsys CEO Sassine Ghazi told analysts that the company has not received a notice from the Commerce Department&#8217;s Bureau of Industry and Security (BIS).
Investors can gain exposure to the stock via&nbsp;AXS Esoterica NextG Economy ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/WUGI#BATS">WUGI</a>) and VanEck Fabless Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMHX#NASDAQ">SMHX</a>).
Price Action: SNPS shares are trading higher by 2.07% to $472 premarket at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45664337/china-tells-us-to-entirely-revoke-wrongful-unilateral-tariffs-after-court-blocks-trumps-liberation-day-levies" target="_blank" rel="noreferrer noopener">China Tells US To &#8216;Entirely&#8217; Revoke &#8216;Wrongful Unilateral&#8217; Tariffs After Court Blocks Trump&#8217;s &#8216;Liberation Day&#8217; Levies</a></li>
</ul>
Photo via Shutterstock

Equities

Large Cap

CDNS

SMHX

SNPS

WUGI

Synopsys Delivers Earnings Win As US Tech Export Curbs Loom Over Industry

<ul>
<li>NVDA</li>
<li>GLD</li>
<li>TSLA</li>
<li>AAPL</li>
<li>BULL</li>
<li>UNH</li>
<li>QQQ</li>
<li>GOOGL</li>
<li>$BTC</li>
<li>CVNA</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

$BTC

AAPL

CVNA

GOOGL

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of May 29, 2025 (Via Swaggy Stocks)

Needham analyst Tom Nikic reiterates Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Foot Lockerto Hold

HC Wainwright &amp; Co. analyst Andrew Fein maintains PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) with a Buy and lowers the price target from $14 to $8.

HC Wainwright & Co. Maintains Buy on PepGen, Lowers Price Target to $8

SentinelOne Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) reported better-than-expected sales for the first quarter after the market <a href="https://www.benzinga.com/quote/S/earnings">close on Wednesday</a>.
SentinelOne reported first-quarter revenue of $229.03 million, beating the consensus estimate of $228.35 million, according to Benzinga Pro. The cybersecurity company reported first-quarter adjusted earnings of two cents per share, in line with analyst estimates.
"Our top-tier growth and margin improvement reflect continued platform momentum and customer success," said Tomer Weingarten, CEO of SentinelOne. "Our innovation engine is fueling adoption across AI, Data, Cloud and Endpoint. With Singularity, we're leading a transformational shift toward AI-powered security for the future."
SentinelOne expects second-quarter revenue of approximately $242 million versus estimates of $244.88 million. The company also lowered its full-year 2026 revenue guidance from $1.007 billion to a range of $996 million to $1.001 billion. Analysts were expecting full-year revenue of $1.01 billion.
SentinelOne shares fell 2.1% to close at $19.67 on Wednesday.
These analysts made changes to their price targets on SentinelOne following earnings announcement.
<ul class="wp-block-list">
<li>Bernstein analyst Peter Weed maintained SentinelOne with an Outperform rating and lowered the price target from $27 to $25.</li>
<li>WestPark Capital analyst Casey Ryan maintained the stock with a Buy and lowered the price target from $31 to $25.</li>
<li>JP Morgan analyst Brian Essex downgraded SentinelOne from Overweight to Neutral and lowered the price target from $22 to $19.</li>
<li>Wells Fargo analyst Andrew Nowinski downgraded the stock from Overweight to Equal-Weight and lowered the price target from $22 to $18.</li>
</ul>
Considering buying S stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="550" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29091236/image-391-1024x550.png" alt="" class="wp-image-931592" style="width:609px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29091236/image-391-1024x550.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29091236/image-391-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29091236/image-391-768x412.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29091236/image-391.png 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45641430/jim-cramer-says-this-quantum-computing-stock-is-so-high-and-too-speculative">Jim Cramer Says This Quantum Computing Stock Is &#8216;So High&#8217; And &#8216;Too Speculative&#8217;</a> </li>
</ul>
Photo via Shutterstock

Markets

These Analysts Slash Their Forecasts On SentinelOne After Q1 Results

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">234.7200</td>
<td align="right">3.480</td>
<td align="right">1.50</td>
<td>89.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">216.8205</td>
<td align="right">1.941</td>
<td align="right">0.90</td>
<td>7.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">102.2800</td>
<td align="right">0.480</td>
<td align="right">0.47</td>
<td>5.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">142.9700</td>
<td align="right">0.370</td>
<td align="right">0.25</td>
<td>13.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">81.7873</td>
<td align="right">0.137</td>
<td align="right">0.16</td>
<td>75.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">50.6600</td>
<td align="right">0.070</td>
<td align="right">0.13</td>
<td>334.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">131.5000</td>
<td align="right">0.020</td>
<td align="right">0.01</td>
<td>18.8K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.20</td>
<td align="right">-0.11</td>
<td align="right">-0.27</td>
<td>2.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.58</td>
<td align="right">-0.20</td>
<td align="right">-0.25</td>
<td>43.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">80.48</td>
<td align="right">-0.05</td>
<td align="right">-0.07</td>
<td>5.0K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For May 29, 2025

Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) shares are trading higher in the premarket session on Thursday after the company beat earnings <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45656415/veeva-announces-fiscal-2026-first-quarter-results" rel="noreferrer noopener">in the first quarter and raised the outlook.</a>
In the after-market session on Wednesday, the company reported adjusted earnings per share of $1.97, beating the analyst consensus estimate of $1.77. Quarterly sales of $759 million (+17% year over year) outpaced the Street view of $731.91 million.
&#8220;We crossed our 2025 revenue run rate goal this quarter and are progressing well toward our 2030 goal to double that and the positive impact we can have for our customers and the industry,&#8221; said CFO Brian Van Wagener. 
Also Read: <a target="_blank" href="https://www.benzinga.com/general/market-summary/25/05/45604787/cathie-wood-reiterates-profound-ai-application-in-healthcare-as-researchers-discover-cancer-survival-outcomes-by-facial-photograph-analysis-here-are-the-stocks-that-could-benefit" rel="noreferrer noopener">Cathie Wood Reiterates &#8216;Profound&#8217; AI Application In Healthcare As Researchers Discover &#8216;Cancer Survival Outcomes&#8217; By Facial Photograph Analysis: Here Are The Stocks That Could Benefit</a>
Subscription services revenues for the first quarter were&nbsp;$634.8 million, an increase of 19% year over year.
Quarterly adjusted operating income for the first quarter jumped 34% year over year to&nbsp;$349.9 million.
Outlook: For the fiscal second quarter ending July 31, Veeva expects total revenue between $766 million and $769 million (Street View: $765.34 million), non-GAAP operating income between $335 million and $337 million and adjusted diluted EPS between $1.89 and $1.90 (Street view: $1.88).
For the full fiscal year ending January 31, 2026, the company projects total revenue between $3.09 billion and $3.10 billion versus the Street view of $3.09 billion (<a href="https://ir.veeva.com/investors/news-and-events/latest-news/press-release-details/2025/Veeva-Announces-Fourth-Quarter-and-Fiscal-Year-2025-Results/default.aspx" target="_blank" rel="noopener">prior view:</a> $3.040 billion to $3.055 billion), non-GAAP operating income of approximately $1.36 billion, and adjusted diluted EPS of around $7.63 versus the Street view of $7.56 (Prior view: $7.32).
Price Action: VEEV shares are trading higher by 14.6% to $268.65 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45664142/why-nvidia-shares-are-trading-higher-by-over-5-here-are-20-stocks-moving-premarket" target="_blank" rel="noreferrer noopener">Why Nvidia Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket</a></li>
</ul>
Photo: Shutterstock

VEEV

Why Veeva Systems Stock Is Gaining Today

<a href="https://www.nytimes.com/2025/05/29/business/media/new-york-times-amazon-ai-licensing.html" title="https://www.nytimes.com/2025/05/29/business/media/new-york-times-amazon-ai-licensing.html">https://www.nytimes.com/2025/05/29/business/media/new-york-times-amazon-ai-licensing.html</a>

AMZN

'The Times And Amazon Announce A.I. Licensing Deal' - NY Times

Wells Fargo analyst Stephen Baxter upgrades HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Underweight to Equal-Weight and raises the price target from $320 to $385.

Upgrades

Wells Fargo Upgrades HCA Healthcare to Equal-Weight, Raises Price Target to $385

Silexion Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced compelling preclinical data demonstrating the efficacy of its next-generation RNAi therapeutic candidate, SIL204, against human pancreatic, colorectal and lung (NSCLC) cancer cell lines. These results significantly expand SIL204's therapeutic potential beyond pancreatic cancer, allowing it to potentially address major KRAS-driven cancers with substantial unmet medical needs.
Following the Company's recent announcement of completion of preclinical studies, a comprehensive analysis of the data has revealed that SIL204 effectively inhibited the proliferation and metabolic activity of human cancer cell lines harboring KRAS G12D mutations across multiple cancer types, resulting in the following obvervations:
<ul>
<li>The data reveals SIL204 successfully inhibited the proliferation and metabolic activity of human cancer cell lines harboring a specific KRAS mutation (G12D): GP2D (colorectal), A427 (lung) and Panc-1 (pancreatic), in a statistically significant manner.</li>
<li>The significant inhibition was observed in a dose-dependent manner down to nanomolar concentrations.</li>
<li>As observed in the left hand graph below (figure 1), a dose-dependent reduction in cell viability was noted in GP2D colorectal cancer cells, even in the absence of external additives, due to the lipid end of SIL204.</li>
<li>Notably, as can be seen in the right hand graph below (figure 2), the Company observed an inhibition rate of approximately 90% in the presence of SIL204 in GP2D colorectal cancer cells.</li>
</ul>
The Company plans to conduct an additional study focused on the inhibition effects of SIL204 on lung (NSCLC) cancer cell lines (A427) in the coming weeks to uncover further data.

SLXN

Silexion Therapeutics Announces Preclinical Results For RNAi Candidate SIL204, Showing Potent Efficacy Against KRAS G12D-Driven Pancreatic, Colorectal, And Lung Cancers

Press Releases

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

MIRA

AN2 Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Aytu BioPharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Gelteq

Grace Therapeutics

IGC Pharma

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

Lipocine

ProPhase Labs

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Scilex Holding

SCYNEXIS

TherapeuticsMD

VYNE Therapeutics

Rodman & Renshaw

Ascendiant Capital

Screenshot 2024-10-02 at 5.44.40 PM

Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game

Screenshot 2024-09-18 at 6.27.57 PM

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

Screenshot 2024-09-04 at 6.19.41 PM

TELO

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs

Screenshot 2024-08-26 at 4.53.37 PM

The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End

Screenshot 2024-07-25 at 6.08.16 PM

MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year

Comments

Mira Pharmaceuticals

空売り

Mira Pharmaceuticals (NASDAQ:MIRA) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル